Abstract
The emergence of microorganisms resistant to a large number of clinically approved antimicrobial agents has emerged as a crisis of global proportions and it has limited the options for the treatment of bacterial infections. As a strategy for combating these microorganisms, the development of drugs with novel mechanisms of action is in evidence. In this context, a new class of antimicrobia…